{
  "id": "5c72b6be7c78d69471000072",
  "type": "list",
  "question": "Which enzymes are inhibited by Duvelisib?",
  "ideal_answer": "Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-\u03b3 in late-stage clinical development for hematologic malignancy treatment.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30067771",
    "http://www.ncbi.nlm.nih.gov/pubmed/28017967",
    "http://www.ncbi.nlm.nih.gov/pubmed/29479062",
    "http://www.ncbi.nlm.nih.gov/pubmed/30094870",
    "http://www.ncbi.nlm.nih.gov/pubmed/29191916",
    "http://www.ncbi.nlm.nih.gov/pubmed/28388280",
    "http://www.ncbi.nlm.nih.gov/pubmed/29233821",
    "http://www.ncbi.nlm.nih.gov/pubmed/27174919",
    "http://www.ncbi.nlm.nih.gov/pubmed/25912635",
    "http://www.ncbi.nlm.nih.gov/pubmed/30033575",
    "http://www.ncbi.nlm.nih.gov/pubmed/29522278"
  ],
  "snippets": [
    {
      "text": "Duvelisib (IPI-145) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K)-\u03b4/\u03b3 isoforms currently in clinical development. PI3K-\u03b4/\u03b3 inhibition may directly inhibit malignant T-cell growth, making duvelisib a promising candidate for patients with peripheral (PTCL) or cutaneous (CTCL) T-cell lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233821",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29191916",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-\u03b4 (PI3K-\u03b4) and PI3K-\u03b3 in late-stage clinical development for hematologic malignancy treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29191916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We observed that pharmaceutical PI3K\u03b3 inhibition with CZC24832 significantly impaired CLL\u00a0cell migration, while dual PI3K\u03b4/\u03b3 inhibitor duvelisib had a greater impact than single isoform-selective inhibitors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29479062",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An oral dual inhibitor of PI3K\u03b3 and PI3K\u03b4, duvelisib, is in clinical trials for the treatment of lymphoid malignancies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29522278",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duvelisib, an oral dual PI3K-\u03b4, \u03b3 inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30033575",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Duvelisib (IPI-145) is an oral dual inhibitor of phosphoinositide-3-kinase (PI3K)-\u03b4 and -\u03b3 in clinical development for the treatment of hematologic malignancies, including indolent non-Hodgkin lymphoma (iNHL). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30033575",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duvelisib, an oral dual PI3K-\u03b4,\u03b3 inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30094870",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-\u03b4 and -\u03b3, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treatment-na\u00efve (TN) CLL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30094870",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Duvelisib targets the PI3K \u03b4 isoform, which is necessary for cell proliferation and survival, and \u03b3 isoform, which is critical for cytokine signaling and pro-inflammatory responses from the microenvironment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The functions of these individual catalytic enzymes have not been fully resolved in AML, therefore using the PI3K p110\u03b4 and p110\u03b3-targeted inhibitor IPI-145 (duvelisib) and specific p110\u03b4 and p110\u03b3 shRNA, we analysed the role of these two p110 subunits in human AML blast survival. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174919",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30067771",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Duvelisib is an orally active dual inhibitor of PI3K-\u03b4 and PI3K-\u03b3 in clinical development in hematologic malignancies (HM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30067771",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duvelisib (IPI-145) is an oral dual inhibitor of phosphoinositide-3-kinase (PI3K)-\u03b4 and -\u03b3 in clinical development for the treatment of hematologic malignancies, including indolent non-Hodgkin lymphoma (iNHL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30033575",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duvelisib (IPI-145) is an oral inhibitor of phosphatidylinositol 3-kinase (PI3K)-\u03b4/\u03b3 isoforms currently in clinical development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PI3K-\u03b4/\u03b3 inhibition may directly inhibit malignant T-cell growth, making duvelisib a promising candidate for patients with peripheral (PTCL) or cutaneous (CTCL) T-cell lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29233821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The functions of these individual catalytic enzymes have not been fully resolved in AML, therefore using the PI3K p110\u03b4 and p110\u03b3-targeted inhibitor IPI-145 (duvelisib) and specific p110\u03b4 and p110\u03b3 shRNA, we analysed the role of these two p110 subunits in human AML blast survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27174919",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duvelisib: a phosphoinositide-3 kinase \u03b4/\u03b3 inhibitor for chronic lymphocytic leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388280",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Duvelisib, a PI3K \u03b4/\u03b3 dual isoform specific inhibitor that induces apoptosis and reduces cytokine and chemokine levels in vitro, holds promise for CLL.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Duvelisib, an oral dual inhibitor of PI3K-\u03b4 and PI3K-\u03b3, is in phase III trials for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28017967",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: Duvelisib targets the PI3K \u03b4 isoform, which is necessary for cell proliferation and survival, and \u03b3 isoform, which is critical for cytokine signaling and pro-inflammatory responses from the microenvironment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28388280",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The purely PI3K-\u03b4-selective inhibitor idelalisib was compared to copanlisib (BAY 80-6946) and duvelisib (IPI-145), with isoform target profiles that additionally include PI3K-\u03b1 or PI3K-\u03b3, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25912635",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, we evaluated how duvelisib affects the activity of the PI3K/Akt signaling pathway and if it has antitumor effects in EBV-associated lymphoma cell lines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29522278",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "phosphoinositide 3-kinase-\u03b4, phosphoinositide 3-kinase-\u03b3"
}